



Geriatrics • Educational evidence summary

Anticholinergic burden in Parkinson disease care

This geriatric evidence summary examines anticholinergic burden in Parkinson disease care.

UnifiedACB • Published October 3, 2026 • Updated October 4, 2026

[Read the current article](#)

<https://unifiedacb.com/articles/029-anticholinergic-burden-in-parkinson-disease-care/>

Separate the mechanism from the medication's clinical role

Parkinson disease care can involve medicines for motor symptoms and additional treatment for sleep, mood, nausea, urinary symptoms or other concerns. A review limited to the primary neurologic prescription can miss relevant exposure elsewhere in the regimen. At the same time, grouping every medication concern under “anticholinergic burden” can obscure important differences in mechanism.

The practical task is to identify the specific question. Is the concern about an antimuscarinic effect, a dopamine-blocking drug, sedation, a source-label ambiguity or another issue? A clear distinction helps prevent the burden score from being used as a substitute for the neurologic assessment.

Understand what the geriatric source is actually flagging

The [AGS Parkinson disease criterion](#) addresses dopamine-receptor antagonism for specified medication groups and retains named exceptions. This is not the same as a source-scale classification of anticholinergic activity. A drug can be relevant to one concern without having the same position in the other framework.

The source also discusses strongly anticholinergic antiparkinsonian medicines in a separate context. These statements should retain their indication and route details. Combining them into one generic warning loses the information needed to understand why a particular medication is being reviewed.

An exception in the Parkinson-related criterion should not be interpreted as a declaration of overall safety. Other effects, indications and clinical circumstances still matter. Conversely, a low anticholinergic category cannot negate a dopamine-blocking concern.

Begin with the current regimen and its timing

Record the exact ingredients, formulations and administration schedule, including medicines prescribed by other clinicians and products obtained without a prescription. Ask what each medicine is intended to accomplish and whether the benefit is present. Actual timing can be important when interpreting fluctuations in function or symptoms.



Distinguish a new symptom from a longstanding one and document recent treatment or health changes. A symptom may relate to the disease, another illness, medication effects or more than one factor. The review should preserve those alternatives rather than selecting a cause from the highest badge.

This article does not recommend altering antiparkinsonian therapy. A change in neurologic treatment requires the treating team's assessment of the regimen and its clinical role. The directory can provide source evidence, but it does not model the consequences of changing the schedule or stopping treatment.

Read medication identity especially carefully

The [public levodopa/decarboxylase inhibitor record](#) is a useful example of source specificity. Its wording describes a combination context, and the preserved KABS anomaly identifies a difference between source documents. The public supplement observation remains an explicit zero while the note retains the main-text discrepancy.

That record should not be generalized into a universal statement about every levodopa formulation or every associated ingredient. Nor should the anomaly be “resolved” by averaging the document values. The correct interpretation names the source version and explains the documented boundary.

Benztropine provides a different identity example. The [public observations](#) retain both the preferred name and the original source spellings. A route-qualified clinical statement about oral benztropine remains narrower than a claim about every possible administration context.

Review the outcomes that matter in this setting

The clinical question may concern mobility, attention, hallucinations, bowel function, urinary symptoms or daily independence. These are distinct outcomes. A medication category does not measure them and should not be used to imply that one mechanism explains all of them.

For a particular product, prescribing information can supply relevant qualifications. The [oxybutynin extended-release label](#) includes a Parkinson disease precaution. That product-specific information can be discussed alongside the source-scale table without changing the table's values or assuming identical evidence for every bladder treatment.

Make the handoff actionable through clarity

A useful review note states the symptom or functional concern, the exact exposure and timing, the relevant source finding and the unanswered question. It also identifies the clinician responsible for assessing any proposed treatment change. This supports coordination without turning an educational tool into an automatic prescribing rule.

If the team changes care, follow the clinical outcome and the original treatment benefit. A smaller burden measure does not itself demonstrate improved mobility or cognition. Where the course remains uncertain, retain that uncertainty rather than reporting a causal conclusion the evidence cannot support.



The practical boundary

Anticholinergic evidence is one component of Parkinson disease medication review. Its value comes from precise source interpretation and careful separation of mechanisms. The person's neurologic status, treatment response and goals remain necessary to decide what the evidence means for care.

References

1. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71:2052-2081. [Source](#)
2. Vennard O, Stewart C, Tolia M, Soiza RL, Myint PK. Anticholinergic Medication Burden Scales: A Systematic Review. J Am Geriatr Soc. 2026;74(6):1771-1784. [Source](#)
3. American Geriatrics Society Beers Criteria Alternatives Panel. Alternative Treatments to Selected Medications in the 2023 AGS Beers Criteria. J Am Geriatr Soc. 2025;73:2657-2677. [Source](#)
4. Fox C, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604-615. [Source](#)
5. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209-220. doi:10.1111/bcp.12617. [Source](#)
6. Egberts A, et al. Anticholinergic Drug Burden and Delirium: A Systematic Review. J Am Med Dir Assoc. 2021;22:65-73.e4. [Source](#)
7. UnifiedACB. Preserved public source-observation dataset, v3.0 RC12 final; inspected for this editorial revision. [Source](#)
8. DailyMed. Oxybutynin chloride extended-release tablets. Official prescribing information; set ID 7d2332b4-9e48-4bb2-a2c3-75e16e1d455b. [Source](#)

Explore the evidence

[Ask UnifiedACB](#) about a medication or source, browse the [Medication Library](#), or read the [methodology](#).

Disclosure

Funding: None. Conflict of interest: None declared for the UnifiedACB educational project.

Educational evidence summary. This content does not provide patient-specific medical advice and does not replace clinical judgment, medication reconciliation, or prescribing guidance.